Repeat hepatectomy justified in patients with early recurrence of colorectal cancer liver metastases: A systematic review and meta-analysis

医学 肝切除术 内科学 荟萃分析 置信区间 科克伦图书馆 结直肠癌 队列研究 队列 外科 胃肠病学 癌症 肿瘤科 切除术
作者
Tessa Hellingman,Merijn E de Swart,Martijn W. Heymans,Elise P. Jansma,Hans van Vliet,Geert Kazemier
出处
期刊:Cancer Epidemiology [Elsevier BV]
卷期号:74: 101977-101977 被引量:19
标识
DOI:10.1016/j.canep.2021.101977
摘要

The benefit of repeat hepatectomy in patients with early recurrence of colorectal cancer liver metastases (CRLM) is questioned, in particular in those suffering from recurrence within three to six months following initial hepatectomy. The aim of this review was therefore to assess whether disease-free interval was associated with overall survival in patients undergoing repeat hepatectomy for recurrent CRLM.A systematic review and meta-analysis was conducted, according to PRISMA guidelines. PubMed, Embase and Cochrane Library databases were searched from database inception to 6th June 2020. Observational studies describing results of repeat hepatectomy for recurrent CRLM, including (disease-free) interval between hepatic resections and overall survival were included. Patients undergoing repeat hepatectomy within three months or additional resection of extrahepatic disease were excluded from meta-analysis.The initial search identified 2159 records, of which 28 were included for qualitative synthesis. A meta-analysis of 15 cohort studies was performed, comprising 1039 eligible patients. Median overall survival of 54.0 months [95 %-CI: 38.6-69.4] was observed after repeat hepatectomy in patients suffering from recurrent CRLM between three to six months compared to 53.0 months [95 %-CI: 44.3-61.6] for patients with recurrent CRLM between seven to twelve months (adjusted HR = 0.89, 95 %-CI: 0.66-1.18; p = 0.410), and 60.0 months [95 %-CI: 52.7-67.3] for patients with recurrent CRLM after twelve months (adjusted HR = 0.70, 95 %-CI: 0.53-0.92; p = 0.012).Disease-free interval is considered a prognostic factor for overall survival, but should not be used as selection criterion per se for repeat hepatectomy in patients suffering from recurrent CRLM.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
芷日月完成签到 ,获得积分10
2秒前
阔达的秀发完成签到,获得积分10
4秒前
吕小布12完成签到,获得积分20
6秒前
westernline完成签到,获得积分10
7秒前
caicai完成签到 ,获得积分10
9秒前
勤奋的白桃完成签到 ,获得积分10
11秒前
生动的凡完成签到 ,获得积分10
11秒前
John完成签到 ,获得积分10
16秒前
鹿呦完成签到 ,获得积分10
17秒前
长情的向真完成签到 ,获得积分10
18秒前
缥缈书本完成签到 ,获得积分10
24秒前
菠萝水手完成签到,获得积分10
26秒前
小冯完成签到 ,获得积分10
26秒前
茉莉完成签到 ,获得积分10
26秒前
gugugu5170完成签到 ,获得积分10
27秒前
刘大壮完成签到 ,获得积分10
28秒前
一逗完成签到,获得积分10
31秒前
二碘化钾完成签到 ,获得积分10
32秒前
希望天下0贩的0应助一逗采纳,获得10
36秒前
hhh完成签到 ,获得积分10
36秒前
song完成签到,获得积分10
42秒前
brodie完成签到,获得积分10
43秒前
星先生完成签到 ,获得积分10
45秒前
梧桐完成签到 ,获得积分10
47秒前
zxdzaz完成签到 ,获得积分10
47秒前
oreo发布了新的文献求助20
52秒前
宁静致远QY完成签到,获得积分10
53秒前
jnoker完成签到,获得积分10
55秒前
晚意完成签到,获得积分10
56秒前
12138完成签到 ,获得积分10
57秒前
尊敬的小凡完成签到,获得积分10
57秒前
li完成签到 ,获得积分10
57秒前
小李完成签到 ,获得积分10
57秒前
csz完成签到,获得积分10
58秒前
LingYun完成签到,获得积分10
59秒前
dola完成签到,获得积分10
1分钟前
清淮完成签到 ,获得积分10
1分钟前
威武雅容完成签到 ,获得积分10
1分钟前
活力蘑菇完成签到 ,获得积分10
1分钟前
务实鞅完成签到 ,获得积分10
1分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
PowerCascade: A Synthetic Dataset for Cascading Failure Analysis in Power Systems 2000
Various Faces of Animal Metaphor in English and Polish 800
Signals, Systems, and Signal Processing 610
Photodetectors: From Ultraviolet to Infrared 500
On the Dragon Seas, a sailor's adventures in the far east 500
Yangtze Reminiscences. Some Notes And Recollections Of Service With The China Navigation Company Ltd., 1925-1939 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 物理 内科学 复合材料 催化作用 物理化学 光电子学 电极 细胞生物学 基因 无机化学
热门帖子
关注 科研通微信公众号,转发送积分 6348466
求助须知:如何正确求助?哪些是违规求助? 8163459
关于积分的说明 17173514
捐赠科研通 5404880
什么是DOI,文献DOI怎么找? 2861802
邀请新用户注册赠送积分活动 1839609
关于科研通互助平台的介绍 1688928